Salute e Benessere

Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd…

"We are thrilled to have Mark join the Board, as a Director of the Company," said Dr. Masood Tayebi, Co-Founder and Chief Executive Officer of Bridgewest Group. "Mark has demonstrated his skills as both an entrepreneur and a visionary with multiple highly successful organizations, and we are excited to have his advice and wisdom at the Board level for Bridgewest Perth Pharma broadly, and more specifically NovaCina's commercial manufacturing of sterile injectables." "We…
PR Newswire
06/03/2024

Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data…

As part of the pre-specified plan, the experts from the IDMC committee at their meeting on February 23 recommended, based upon their evaluation of the unblinded medical and clinical statistical data from 103 patients, that the CLINGLIO trial should continue without modification. This interim analysis was conducted following the committee's assessment of the efficacy – survival without progression (tumor growth or clinical deterioration) – of LAM561 after 45 progression events have occurred. This…
PR Newswire
06/03/2024

H+H International A/S appoints new Chief Financial Officer

Bjarne Pedersen joined H+H with an auditing and banking background and has worked for H+H for more than 15 years. Bjarne has held various managerial roles across H+H, including responsibilities in areas such as Corporate Finance, IT, Investor Relations, and most recently as Chief Strategy Officer. Bjarne Pedersen joined H+H with an auditing and banking background and has worked for H+H for more than 15 years. Bjarne has held various managerial roles across H+H, including…
PR Newswire
06/03/2024

Endotronix Presents Positive PROACTIVE-HF Clinical Trial Results for its…

"These results are very encouraging and provide strong evidence in favor of HF management using PA pressure-guided therapy, along with vital sign data, to remotely optimize guideline-directed medical therapy and improve heart failure outcomes," stated Dr. Klein, Section Chief of Advanced Heart Failure, Mechanical Circulatory Support, Pulmonary Hypertension, and Heart Transplant at the University of California San Francisco and national principal investigator of the PROACTIVE-HF trial…
PR Newswire
06/03/2024

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American…

Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies evaluating ADCT-601 targeting AXLLAUSANNE, Switzerland, March05, 2024(GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be...
Nasdaq GlobeNewswire
05/03/2024

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at…

Poster Presentation Details Abstract 734, “Inhibition of equilibrative nucleoside transporter 1 relieves intracellular adenosine-mediated immune suppression” Session: Experimental and Molecular Therapeutics: Tumor MicroenvironmentDate and Time: Sunday, April 7, 2024, 1:30 PM - 5:00 p.m. PTLocation: Poster Section 29 About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of...
Nasdaq GlobeNewswire
05/03/2024

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and…

Five abstracts accepted for poster presentation highlight company's differentiated antibody-drug conjugate and multispecific antibody clinical product candidates Strong preclinical activity across multiple FRα-expressing indications for ZW191, a FRα-targeting antibody-drug conjugateNext generation trispecific T cell engager platforms with integrated CD28 costimulation demonstrate durable anti-tumor activity VANCOUVER, British Columbia, March05, 2024(GLOBE NEWSWIRE) -- Zymeworks Inc...
Nasdaq GlobeNewswire
05/03/2024

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 12 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 5, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or...
Nasdaq GlobeNewswire
05/03/2024

Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating…

Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results Expect to report DREAM U.S. pivotal study efficacy and safety data by early April Achieved record quarterly sales of €1.8 millionMont-Saint-Guibert, Belgium – March 5, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep...
Nasdaq GlobeNewswire
05/03/2024

Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21…

Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024 Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the full year 2023, after U.S. markets close on Wednesday, March 20, 2024.Following the release, Alvotech will conduct a conference call for analysts on Thursday, March 21, 2024, at 8:00 am ET (12 noon...
Nasdaq GlobeNewswire
05/03/2024

Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue…

Recent Tissue Distribution Study of LPT-CBD to the brain The Company announces the results of a recent tissue distribution study of its liposome CBD platform (LPT-CBD), that indicated the potential of LPT-CBD to support a new therapeutic venue for neurological disorders. The fundamentals of Innocan's LPT-CBD platform lay in its ability to slowly-release CBD into the blood stream following a single subcutaneous injection. Recent pharmacokinetic studies conducted in various...
PR Newswire
05/03/2024

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of…

Company announcement – No. 11 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 5, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 102,581 divided into 102,581 new shares with a nominal value of DKK 1...
Nasdaq GlobeNewswire
05/03/2024

More than 1,077.57 Billion Units of Disposable Gloves to be Sold in the Next 6…

Browse in-depth TOC on the Disposable Gloves Market Browse in-depth TOC on the Disposable Gloves Market 615 – Pages 422 - Tables 237 - Figures Disposable Gloves Market Report Scope The global disposable gloves market is dynamic and responsive to the evolving needs of various industries. While environmental concerns and supply chain disruptions persist, the market continues to grow, driven by regulatory compliance, technological advances,...
PR Newswire
05/03/2024

Sandoz receives FDA approval for first and only denosumab biosimilars

MEDIA RELEASEWyost ®(denosumab-bddz) and Jubbonti ®(denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva® * (denosumab) and Prolia ® * (denosumab)FDA approval based on robust clinical studies and totality of evidence, which show no clinically meaningful differences from reference medicinesBasel, March 5, 2024– Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug...
Nasdaq GlobeNewswire
05/03/2024

Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth…

Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up Leuven, BELGIUM, 05 March – 07.00 PM CET– Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has received an aggregate amount of EUR 300,000 in the framework of the Atlas Funding Program. On March 4, 2024, the Company issued the Tenth Tranche consisting of 12 convertible bonds, for an aggregate amount ofEUR 300,000...
Nasdaq GlobeNewswire
05/03/2024

The Industrial Dust Collector Market to Surpass Revenue of Over $10.43 Billion…

Browse in-depth TOC on the Industrial Dust Collector Market Browse in-depth TOC on the Industrial Dust Collector Market 293 – Pages 113 - Tables 91 - Figures Industrial Dust Collector Market Report Scope • Rising Mining Activities Driving Industry Growth The global industrial dust collector market is driven by increasing prominence on environmental sustainability, workplace safety, and regulatory compliance across several industries...
PR Newswire
05/03/2024

Monthly information related to total number of voting rights and shares…

Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024 Article 223-16 of general regulation of French Autorité des Marchés FinanciersListing markets:Euronext Paris from Euronext (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) &Nasdaq Global Select Market in the United-States (Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut(1)...
Nasdaq GlobeNewswire
05/03/2024

Life Fitness Delivers on the Future of Fitness, Debuting State-of-the-Art Cardio…

The Symbio product series fuses advanced biomechanics, luxurious yet purposeful design, and personalized, immersive experiences to create the ultimate multi-sensory fitness experience. Symbio's meticulous engineering works seamlessly with the versatilities of the human body to craft workouts as unique as the individuals using the machines. The Symbio product series fuses advanced biomechanics, luxurious yet purposeful design, and personalized, immersive experiences to create the ultimate...
PR Newswire
05/03/2024

Fierce Medtech Names Enable Injections a "Fierce 15" Company of 2023

enFuse is designed for compatibility with small molecule and biologic drug formulations across a wide range of viscosities and volumes (5-25mL for a single device, and up to 100mL with multiple devices). The recognition from Fierce follows the recent U.S. FDA approval and launch of the first combination product utilizing the enFuse technology. Enable is currently working with a number of pharma partners to advance several ongoing clinical studies evaluating their therapies in combination with…
PR Newswire
05/03/2024

Orthopedic Braces & Supports Market Worth $5.1 billion | MarketsandMarkets™

Browse in-depth TOC on "Orthopedic Braces & Supports Market" Browse in-depth TOC on "Orthopedic Braces & Supports Market" 192 - Tables 47 - Figures 312 - Pages Orthopedic Braces & Supports Market Scope: Product segment to register significant growth rate over the forecast period of 2023-2029. Based on the product, the global orthopedic braces and supports market is segmented into Knee, Ankle, foot walkers, Hip, Back, and Spine, Shoulder, Elbow, Hand, Wrist...
PR Newswire
05/03/2024

Kohler x SR_A Announce Limited-Edition Smart Toilet 'Formation 02' and…

"Formation 02 furthers our celebrated partnership with SR_A and Dr. Samuel Ross, bringing new and unexpected design and exemplifying Kohler's history of design and innovation excellence," says Scott Edmunds, VP of Kohler Marketing. "Formation 02 combines our industrial expertise and technological prowess with our strong belief in the power of creativity to challenge and drive forward progress." "Formation 02 furthers our celebrated partnership with SR_A and Dr.Samuel…
PR Newswire
05/03/2024

STEVENSON SEARCH PARTNERS RECEIVES INVESTMENT TO SPUR GROWTH AS A LEADING TALENT…

Stevenson Search Partners is an established and trusted executive search advisor servicing the global biotechnology, pharmaceutical, medical technology, contract research organization (CRO) and contract development manufacturing organization (CDMO) sectors. Stevenson Search Partners is an established and trusted executive search advisor servicing the global biotechnology, pharmaceutical, medical technology, contract research organization (CRO) and contract development manufacturing…
PR Newswire
05/03/2024

Novartis shareholders approve all resolutions proposed by the Board of Directors…

Shareholders approve 27 thconsecutive dividend increase to CHF 3.30 (+3.1%) per share for 2023; representing a 3.7% yield 1and approximately 58% payout of free cash flowShareholders confirm Joerg Reinhardt as Chair of the Board of Directors as well as all other current members Shareholders approve all other proposals of the Board of Directors, including the reduction of share capital, the 2023 report on non-financial matters (for the first time submitted to...
Nasdaq GlobeNewswire
05/03/2024

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity…

"We are very pleased to bring these tools to the market as they represent the culmination of a close partnership with the neuroscience community," said Dr. Yuling Luo, Founder, Chairman & CEO of Alamar. "This "first-in-class" panel content was provided by leading researchers in pharma and academia who were looking for a more comprehensive way to look at CNS diseases while maintaining the high sensitivity required to detect critical biomarkers in plasma and CSF. We…
PR Newswire
05/03/2024
Altri  Comunicati